Phase 2 Readout~quarter

Phase 2 Readout: mze829

December 31, 2026

Company: Maze Therapeutics, Inc. (MAZE)
Drug: mze829
Indication: broad AMKD

Track this catalyst and more

Get real-time alerts, AI-powered analysis, and full catalyst coverage.

Start Free Full Calendar